Analyst picks & changes
(CEPH)
(CHIR)
Analysts were virtually — but not quite — unanimous in their rave reviews of data from CEPH's Phase II/III trial of Myotrophin
in amyotrophic lateral sclerosis (see BioCentury Extras June 12 and 13).
Peter Ginsberg of Vector Securities International expects Myotrophin to rapidly penetrate the $250 million U.S. ALS market because there's no approved treatment, the disease is almost uniformly
